WHO naming stem · suffix · 29 listed names
-anib
This page was written with AI.
angiogenesis inhibitors
Where it sits in a name
WHO writes the stem as -anib. So the letters anib sit at the end of the name (…anib).
All 29 names WHO lists under -anib
These are the INN in group (a) of Part IV of the stem book: names in which WHO says the stem is used as defined. The stem is marked where WHO places it. A-Z as WHO lists them.
Beside each name: the brand names it appears under in the US list (FDA Drugs@FDA) and the EU central list (EMA), or that neither list carries it. 5 of 29 names appear in these lists: 5 in the US list (FDA Drugs@FDA) and 5 in the EU central list (EMA); 4 have national brands in at least one EU/EEA country. Each brand opens in this site's brand lookup. A name is found when the agency's ingredient name is the same name once salt words such as hydrochloride or sodium are set aside (the list of those words); where WHO's own name carries such a word (estradiol valerate), the agency must write the same words. A spelling that differs only by the INN letter rules (ph for f, y for i) is found too and shown. Under each name that one or more EU/EEA countries authorise under a national brand of their own (through that country's agency, so not in the EU central list), a line now gives the number of those countries and their codes, from EMA's Article 57 data, and opens the country lookup at that name. A name with none of these lines may still be sold elsewhere, or in Europe only under its own generic name.
- acrizanibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- alofanibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- beloranibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- bevasiranibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- brivanib alaninateNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- cediranibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- crenolanibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- foslinanibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- linifanibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- lucitanibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- motesanibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- necuparanibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- nintedanibUS brands: OFEV
- opaganibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- pazopanibUS brands: VOTRIENTEU (central) brands: Votrient
- pegaptanib
- pegdinetanibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- pegpleranibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- risuteganibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- rivoceranibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- semaxanibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- timtraxanibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- tivozanibUS brands: FOTIVDAEU (central) brands: Fotivda
- toceranibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- trebananibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- umedaptanib pegolNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- vandetanibUS brands: CAPRELSAEU (central) brands: Caprelsa
- vatalanibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- vorolanibNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
US list: Drugs@FDA, from the FDA Drugs@FDA data (openFDA bulk file), checked . It keeps discontinued brands, marked here as FDA marks them.
EU (central) list: EMA medicines list, European Medicines Agency (EMA), checked . Medicines authorised for the whole EU through EMA only: a brand authorised by one country's own agency is not in it. Source: European Medicines Agency (EMA), medicines list, checked 2026-09-24.
EU/EEA national lists: European Medicines Agency (EMA), Article 57 product data, downloaded (EMA's Article 57 page). Brand names authorised by each country's own agency, as the country lookup reads them; a product named after its substance and maker ("Paracetamol Teva") is not counted as a brand, and EU central authorisations are not counted as a country. GB in a list is Northern Ireland, which EMA's data carries alongside the EU/EEA countries.
Decode another name
Decoded
alofanib
Listed INNCarries the WHO stem -anib
- -anibend of the nameWHO lists it hereWHO definition: angiogenesis inhibitors
“alofanib” is an INN that WHO lists under -anib in the 2024 stem book.
The same decoder as the front page: it reads the letters of a name against all 482 WHO stems, in your browser.
Source and licence
The definition of -anib (Part II B) and the 29 names (Part IV, group (a)) are from Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024 (World Health Organization, Stem book 2024 (ISBN 978-92-4-009938-8); covers proposed INN Lists 1-129). Checked .
Adapted from: Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO. This adaptation was not created by WHO; WHO is not responsible for its content or accuracy and does not endorse this site. The data file stems.json is shared under the same licence.